WallStSmart

BioNexus Gene Lab Corp Common stock (BGLC)vsSherwin-Williams Co (SHW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sherwin-Williams Co generates 450603% more annual revenue ($23.94B vs $5.31M). SHW leads profitability with a 10.9% profit margin vs -54.7%. SHW earns a higher WallStSmart Score of 56/100 (C).

BGLC

Avoid

26

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 7.52

SHW

Buy

56

out of 100

Grade: C

Growth: 5.3Profit: 7.5Value: 5.3Quality: 4.0
Piotroski: 4/9Altman Z: 1.54
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BGLC.

SHWUndervalued (+4.8%)

Margin of Safety

+4.8%

Fair Value

$320.70

Current Price

$300.09

$20.61 discount

UndervaluedFair: $320.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BGLC3 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.5210/10

Safe zone — low bankruptcy risk

SHW2 strengths · Avg: 9.5/10
Return on EquityProfitability
58.7%10/10

Every $100 of equity generates 59 in profit

Market CapQuality
$73.12B9/10

Large-cap with strong market position

Areas to Watch

BGLC4 concerns · Avg: 2.5/10
Market CapQuality
$5.56M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-35.9%2/10

ROE of -35.9% — below average capital efficiency

Revenue GrowthGrowth
-98.9%2/10

Revenue declined 98.9%

SHW4 concerns · Avg: 4.0/10
PEG RatioValuation
2.294/10

Expensive relative to growth rate

P/E RatioValuation
28.5x4/10

Moderate valuation

Price/BookValuation
16.6x4/10

Trading at 16.6x book value

Altman Z-ScoreHealth
1.544/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BGLC

The strongest argument for BGLC centers on Price/Book, Debt/Equity, Altman Z-Score.

Bull Case : SHW

The strongest argument for SHW centers on Return on Equity, Market Cap.

Bear Case : BGLC

The primary concerns for BGLC are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : SHW

The primary concerns for SHW are PEG Ratio, P/E Ratio, Price/Book. Debt-to-equity of 3.11 is elevated, increasing financial risk.

Key Dynamics to Monitor

BGLC profiles as a turnaround stock while SHW is a value play — different risk/reward profiles.

BGLC carries more volatility with a beta of 2.19 — expect wider price swings.

SHW is growing revenue faster at 6.8% — sustainability is the question.

SHW generates stronger free cash flow (800,000), providing more financial flexibility.

Bottom Line

SHW scores higher overall (56/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BioNexus Gene Lab Corp Common stock

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.

Sherwin-Williams Co

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Sherwin Williams Company is a Cleveland, Ohio based company in the paint and coating manufacturing industry. The company primarily engages in the manufacture, distribution, and sale of paints, coatings, floorcoverings, and related products to professional, industrial, commercial, and retail customers primarily in North and South America and Europe.

Want to dig deeper into these stocks?